Results 191 to 200 of about 58,483 (238)

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Transmitted and pretreatment drug resistance among 69 HIV-1 CRFs in China: the first systematic analysis. [PDF]

Emerg Microbes Infect
Yin X, Zhao B, An M, Wang D, Liu Z, Shang H, Han X.   +6 more
europepmc   +1 more source

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. [PDF]

J Comp Eff Res
Curteis T, Eddowes LA, Karlsson A, Luedke H, Rubinstein M, Hempfling M, Gurney J, Gandhi-Patel B, Unger N, Mordi U, Chen M, Jarrett J, Sherman EM, Mounzer K, Khalsa AM, Dinges WL, McKellar MS, Lipps A.   +17 more
europepmc   +1 more source

Protein language model embeddings improve HIV drug resistance prediction: a comprehensive benchmark with attention-based interpretability. [PDF]

Bioinformatics
Farquhar H.
europepmc   +1 more source

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? [PDF]

Curr HIV/AIDS Rep
Debroy P, Lake JE.
europepmc   +1 more source

HIV-1 drug resistance and associated risk factors in patients with antiretroviral therapy failure in Chongqing, China, 2019-2023. [PDF]

PLoS One
Zhang H, Wu P, Ye W.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

HIV Protease Inhibitors

Current Pharmaceutical Design, 1996
The protease encoded by the human immunodeficiency virus (HIV protease) mediates the maturation of newly formed HIV particles through proteolytic processing of the gag and gag-pol gene products. Because of its essential role in the HIV replication cycle, this enzyme represents a logical target for the treatment of HIV infection.
H L Sham, D J Kempf
exaly   +14 more sources

HIV-Protease Inhibitors

New England Journal of Medicine, 1998
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
Charles Flexner, Flexner Charles
exaly   +17 more sources

Resistance to HIV protease inhibitors

Haemophilia, 1998
Summary. Resistance to the HIV‐1 protease inhibitor indinavir involves the accumulation of multiple amino acid substitutions in the viral protease. A minimum of 11 amino acid positions have been identified as potential contributors to phenotypic resistance.
C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, J. H. CONDRA   +5 more
openaire   +2 more sources